Computer vs expert: can AI match humans in finding hidden leukemia?
NCT ID NCT07269067
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at 60 people with acute myeloid leukemia to see if a computer method (FlowSOM) can detect leftover cancer cells as well as expert analysis. Researchers will compare results from both methods using stored blood samples. If the computer approach works, it could make testing faster and more reliable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could make detecting leftover leukemia cells faster and more consistent, helping doctors make better treatment decisions.
- What could go wrong
- This is a small, early-stage study looking back at past data, so results may not apply to all patients or hospitals. The computer method might miss some cases that experts catch.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a fourth drug tip the scales against an aggressive leukemia?
- Double-Barreled attack: Gene-Edited stem cells and CAR T-Cells take on tough leukemia
- New drug combination targets rare childhood leukemia that resists standard treatment
- New combo aims to boost survival in older AML patients
- New combo therapy for AML enters early human testing
- New hope for older AML patients: triple drug combo aims to control disease and prevent relapse